Navigation Links
BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
Date:1/28/2008

NOVATO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today the appointment of Dr. Gordon Vehar as Vice President of Research. Former Vice President of Research and Development for Raven Biotechnologies, Dr. Vehar is the inventor of numerous biotechnology patents and the recipient of a collection of prestigious scientific awards including two Distinguished Inventor of the Year Awards from Intellectual Property Owners, Inc.

"We are very pleased to welcome Dr. Vehar to BioMarin. He brings with him extraordinary research and drug development experience and his contributions will substantially bolster our efforts to grow our early pipeline at BioMarin," said Dr. Emil Kakkis, Senior Vice President and Chief Medical Officer.

Dr. Vehar also served in various roles throughout a 20-year tenure with Genentech, including Director of Cardiovascular Research and Staff Scientist for Cardiovascular Research and Protein Chemistry. Also at Genentech, he served as Project Team Leader on various drug discovery and development projects, which yielded four marketed products. He is the recipient of the Murray Thelin Award for Outstanding Research presented by the National Hemophilia Foundation, the Inventor of the Year Award given by Intellectual Property Owners, Inc., for the human tissue plasminogen activator (t-PA) patent for the treatment of heart attacks and stroke, and the Distinguished Inventor of the Year Award from Intellectual Property Owners, Inc. for the patent on recombinant Factor VIII, a genetically engineered clotting factor enabling production of a therapeutic product for treating hemophilia A. Dr. Vehar has served on the Scientific Advisory Board for the Oklahoma Center for Molecular Medicine, he is an inventor with 37 issued patents and is the author of more than 35 publications. Dr. Vehar received a Ph.D. from the University of Cincinnati Medical School.

Dr. Vehar joins two other new executives recently appointed to BioMarin: Steve Glass, Vice President and General Manager of European Operations and Lewis Chapman, Vice President of Global Marketing. Recent internal leadership appointments include Luisa Bigornia, Vice President of Intellectual Property, and Dr. Charles O'Neill, Vice President of Pharmacological Sciences.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about the development and commercialization of products; actions by regulatory authorities; and statements regarding the development of its product candidates. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results and timing of current and planned clinical trials; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) and Naglazyme(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Contact:

Investors: Media:

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

+ 1 415 506 6570 + 1 415 506 6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin to Present at the BioCentury NewsMakers Conference
5. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
8. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):